<DOC>
	<DOC>NCT01088893</DOC>
	<brief_summary>This is a randomized controlled pilot study investigating signals involved in drug resistance to chemotherapy. Patient will be randomized to undergo observation or to receive Everolimus after completion of neoadjvuant treatment (anthracycline and/or taxane-based) and before surgery. The patients will be monitored for efficacy and safety.</brief_summary>
	<brief_title>Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Women aged ≥ 18 years; Histologically and/or cytologically confirmed invasive ductal or lobular breast cancer; Tumor of 3 cm or greater at time of diagnosis Measurable primary tumor after neoadjuvant treatment before randomization No prior chemotherapy for breast cancer; ECOG performance status ≤1 or Karnofsky performace status ≥ 70% Adequate liver/renal function Able to swallow whole tablets. Able to give written informed consent Able to follow prescription instructions reasonably well Male patient Prior history of other malignancy within 5 years of study entry, aside from contralateral breast carcinoma, appropriately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin Distant metastasis, including skin involvement beyond the breast area Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>everolimus</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>m-TOR inhibitor</keyword>
</DOC>